Bafna Pharmaceuticals Limited Share Price

Equities

BAFNAPH

INE878I01022

Pharmaceuticals

End-of-day quote NSE India S.E. 03:30:00 18/06/2024 am IST 5-day change 1st Jan Change
77.11 INR -5.00% Intraday chart for Bafna Pharmaceuticals Limited -5.00% -16.18%
Sales 2022 85Cr 1.02Cr Sales 2023 115.35Cr 1.38Cr Capitalization 193.98Cr 2.32Cr
Net income 2022 5.1Cr 6L Net income 2023 11Cr 13.53L EV / Sales 2022 3.65 x
Net Debt 2022 11Cr 13.03L Net Debt 2023 15Cr 18.09L EV / Sales 2023 1.81 x
P/E ratio 2022
58.4 x
P/E ratio 2023
17.1 x
Employees 588
Yield 2022 *
-
Yield 2023
-
Free-Float 10.36%
More Fundamentals * Assessed data
Dynamic Chart
Bafna Pharmaceuticals Limited Approves the Appointment of A. Mohanachandran as Company Secretary and Compliance Officer CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Bafna Pharmaceuticals Limited Announces the Inauguration of New Quality Control Laboratory CI
Bafna Pharmaceuticals Limited Announces Resignation of Vishnu Vasudeva Kuppa as Company Secretary and Compliance Officer CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Bafna Pharmaceuticals Resumes Commercial Production of Manufacturing Units in Chennai, India MT
Bafna Pharmaceuticals Limited Announces Commercial Production CI
Floods Disrupt Bafna Pharmaceuticals' Manufacturing Plant in Chennai, India MT
Bafna Pharmaceuticals Limited Announces Suspension of Chennai Production Activity Due to Impact of Michaung Cyclone CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Bafna Pharmaceuticals Limited Announces Resignation of Kamlesh Kumar Babulal as Non-Executive Independent Director from the Board CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Bafna Pharmaceuticals Limited Approves Board Appointment CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
More news
1 day-5.00%
1 week-5.00%
Current month-14.27%
1 month-18.53%
3 months-3.19%
6 months-18.10%
Current year-16.18%
More quotes
1 week
77.11
Extreme 77.11
78.00
1 month
77.11
Extreme 77.11
89.95
Current year
75.90
Extreme 75.9
113.00
1 year
75.90
Extreme 75.9
119.00
3 years
75.90
Extreme 75.9
185.50
5 years
4.40
Extreme 4.4
233.55
10 years
4.40
Extreme 4.4
233.55
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 01/81/01
Director of Finance/CFO - -
Members of the board TitleAgeSince
Chief Executive Officer 62 01/81/01
Director/Board Member 63 26/23/26
Director/Board Member - -
More insiders
Date Price Change Volume

End-of-day quote NSE India S.E., June 18, 2024

More quotes
Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Company’s subsidiary is Bafna Lifestyles Remedies Limited.
More about the company
  1. Stock Market
  2. Equities
  3. BAFNAPH Stock